IRX4204 for Plaque Psoriasis
(IRX4204-Psoria Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are: * Does IRX4204 treat plaque psoriasis symptoms? * Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated? * What medical problems do participants have when taking IRX4204? Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis. Participants will: * Take IRX4204 every day for 28 days * Visit the clinic once every week for checkups and tests * Complete specific assessments about plaque psoriasis and changes to plaques
Will I have to stop taking my current medications?
The trial requires participants to stop certain medications before starting. You must stop biologics 12 weeks before, systemic immunosuppressives 4 weeks before, and topical medications 2 weeks before the trial begins.
Eligibility Criteria
This trial is for adults with mild to moderate plaque psoriasis. Participants must be willing to take a daily dose of the study medication or placebo for 28 days and visit the clinic weekly for checkups and tests. The specific eligibility criteria are not provided, but typically participants should not have other serious health issues that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take IRX4204 every day for 28 days and visit the clinic once every week for checkups and tests
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- IRX4204
Find a Clinic Near You
Who Is Running the Clinical Trial?
Io Therapeutics
Lead Sponsor